![](https://endpts.com/wp-content/uploads/2023/10/William-Dongfang-Shi-Atom-Bioscience-CEO.jpg)
William Dongfang Shi, Atom Bioscience CEO and founder
Atom Bioscience raises $83M in Series D for URAT1 inhibitor in chronic gout treatment
Atom Bioscience has pulled in $83 million in Series D financing for its URAT1 inhibitor for chronic gout, the company announced …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.